Research Topics
| J P BrownSummaryCountry: Canada Publications
| Collaborators
|
Detail Information
Publications
Low urine pH and acid excretion do not predict bone fractures or the loss of bone mineral density: a prospective cohort studyTanis R Fenton
Department of Community Health Sciences, Faculty of Medicine, University of Calgary TRW Building, 3rd Floor, 3280 Hospital Drive NW, Calgary, Alberta T2N 4Z6, Canada
BMC Musculoskelet Disord 11:88. 2010..8x phosphate + organic acids] minus [sodium + potassium + 2x calcium + 2x magnesium mEq] in fasting morning urine predict: a) fragility fractures; and b) five-year change of bone mineral density (BMD) in adults...- Evaluation of easily measured risk factors in the prediction of osteoporotic fracturesRobert Bensen
Medical Science, McMaster University, Hamilton, Ontario, Canada
BMC Musculoskelet Disord 6:47. 2005..As few premonitory symptoms for fracture exist, it is of critical importance that physicians effectively and efficiently identify individuals at increased fracture risk... - Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosisClaus Christiansen
Center for Clinical and Basic Research, Ballerup, Denmark
BMC Musculoskelet Disord 11:130. 2010..We report the safety findings from a 3-year phase 3 study (NCT00205777) of bazedoxifene, a novel selective estrogen receptor modulator under development for the prevention and treatment of postmenopausal osteoporosis... - A community-based clinical trial of Intra-Venous zOledRonic acid once Yearly in comparison to oral bisphosphonates in postmenopausal women with osteoporosis: the IVORY trial Methodological considerationsJacques P Brown
Centre de recherche du CHUQ, CHUL, Laval University, Quebec City, Quebec, Canada
Contemp Clin Trials 32:741-6. 2011..IVORY is a Canadian post marketing study aiming at assessing real-life effectiveness, health care resource utilization, safety and compliance to treatment with zoledronic acid in comparison to orally administered bisphosphonates (OBP)... - Bone turnover markers in the management of postmenopausal osteoporosisJacques P Brown
Universite Laval, Quebec, QC, Canada
Clin Biochem 42:929-42. 2009.... - Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trialJacques P Brown
Laval University, Le Centre Hospitalier Universitaire de Quebec, Quebec City, Quebec, Canada
J Bone Miner Res 24:153-61. 2009..Denosumab showed significantly larger gains in BMD and greater reduction in bone turnover markers compared with alendronate. The overall safety profile was similar for both treatments... - Improvement of pagetic bone lesions with risedronate treatment: a radiologic studyJ P Brown
Le Centre Hospitalier Universitaire de Quebec, Sainte Foy, Canada
Bone 26:263-7. 2000..Risedronate treatment had no deleterious effect on osteolytic lesions in weight-bearing bones; indeed, the majority of lesions with osteolytic fronts were improved after 6 months of risedronate treatment... - Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy studyJacques P Brown
Laval University and Le Centre Hospitalier Universitaire de Québec, Quebec City, Quebec, Canada
J Bone Miner Res 26:2737-44. 2011..Biochemical markers were comparable to and highly correlated with pretreatment levels. These data confirm that the effects of denosumab on bone turnover at the tissue level are fully reversible... - Positive effect of etidronate therapy is maintained after drug is terminated in patients using corticosteroidsJ P Brown
Centre de Recherche du CHUL, Centre Hospitalier Universitaire de Quebec, 2705 boul Laurier S 784, Ste Foy, Quebec, G1V 4G2 Canada
J Clin Densitom 4:363-71. 2001..Following the discontinuation of etidronate therapy, there was no accelerated bone loss and there was evidence of a residual protective effect in both the lumbar spine and femoral neck for up to 1 yr posttreatment... - The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosisJ P Brown
Le Centre de Recherche du CHUL, Laval University, Sainte Foy, Quebec, Canada
Calcif Tissue Int 71:103-11. 2002.... - Ability of peripheral DXA measurement to diagnose osteoporosis as assessed by central DXA measurementD Picard
Department of Nuclear Medicine, Hopital Saint Luc, Universite de Montreal, Montreal, Quebec, Canada
J Clin Densitom 7:111-8. 2004.... - The impact of two educational interventions on osteoporosis diagnosis and treatment after fragility fracture: a population-based randomized controlled trialL Bessette
Department of Medicine, CHUL Research Centre, Laval University, Quebec City, PQ, Canada
Osteoporos Int 22:2963-72. 2011..Educating patients about osteoporosis had little impact on whether a woman received an osteoporosis diagnosis or treatment... - Factors influencing the treatment of osteoporosis following fragility fractureL Bessette
Department of Medicine, CHUL Research Centre, Laval University, Quebec City, PQ, Canada, GIV 4G2
Osteoporos Int 20:1911-9. 2009.... - Algorithms can be used to identify fragility fracture cases in physician-claims databasesS Jean
National Institute of Public Health of Quebec, 945, Wolfe Avenue, Quebec, QC G1V 5B3, Canada
Osteoporos Int 23:483-501. 2012.... - The care gap in diagnosis and treatment of women with a fragility fractureL Bessette
Laval University, Rheumatology and Immunology Research Centre, CHUL Research Centre, Quebec, QC, Canada
Osteoporos Int 19:79-86. 2008..Despite fragility fractures being common in this population osteoporosis is under-diagnosed and under-treated... - Paget disease of bone: mapping of two loci at 5q35-qter and 5q31N Laurin
Molecular Endocrinology and Oncology Research Center, CHUL Research Center, Quebec, QC, Canada G1V 4G2
Am J Hum Genet 69:528-43. 2001..It is proposed that the 5q35-qter and 5q31 loci be named "PDB3" and "PDB4," respectively... - Use of phalangeal bone mineral density and multi-site speed of sound conduction to monitor therapy with alendronate in postmenopausal womenW M Drake
Osteoporosis Research Center, University of British Columbia, Vancouver, Canada
Osteoporos Int 13:249-56. 2002..05 to 0.22; and between SOS and TH DXA ranged from -0.08 to 0.10 (all p = NS). These data suggest that the response to alendronate therapy over this time period cannot be measured by accuDXA or Sunlight SOS at the sites studied... - Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosisS Adami
Riabilitazione Reumatologica, University of Verona, Valeggio s Mincio, Verona, Italy
Osteoporos Int 19:87-94. 2008..Sequential raloxifene prevented rapid bone loss at lumbar spine and further increased bone mineral density (BMD) at femoral neck, whether raloxifene was started immediately or after a one-year delay following teriparatide treatment... - Effectiveness of alendronate and etidronate in the treatment of osteoporosis in men: a prospective observational studyW P Olszynski
Saskatoon Osteoporosis Centre, Saskatoon, SK, S7K 0H6, Canada
Osteoporos Int 17:217-24. 2006..The effect of these two bisphosphonates on fractures and FN BMD in osteoporotic men is likely positive, but requires further study... - Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosisS T Harris
University of California, San Francisco, California 94117, USA
Curr Med Res Opin 20:757-64. 2004..The efficacy and tolerability of risedronate once-a-week dosing (35 and 50mg) were compared with risedronate daily dosing (5mg) in a 2-year study in women with osteoporosis... - The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis StudyA Papaioannou
Division of Geriatric Medicine, McMaster University, Hamilton Health Sciences Chedoke Site, 1200 Main Street West, Hamilton, ON L8N 3Z5, Canada
Osteoporos Int 19:581-7. 2008..The need to treat fragility fractures is well established in guidelines, and these numbers represent an important care gap... - Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosisJ P Devogelaer
Saint Luc University Hospital, Universite Catholique de Louvain, Bruxelles, Belgium
Osteoporos Int 18:1211-8. 2007..BMD increased significantly. Bone turnover markers decreased from baseline and were maintained within premenopausal reference ranges... - Associations among disease conditions, bone mineral density, and prevalent vertebral deformities in men and women 50 years of age and older: cross-sectional results from the Canadian Multicentre Osteoporosis StudyD A Hanley
Department of Medicine, University of Calgary Calgary, Alberta, Canada
J Bone Miner Res 18:784-90. 2003..The importance of these associations for osteoporosis case finding and management require further and prospective studies... - The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across CanadaJ D Adachi
Department of Medicine, St Joseph's Hospital, McMaster University, Hamilton, Ontario Canada
Osteoporos Int 12:903-8. 2001..In conclusion, HRQL was lower in the physical functioning domain in women and the role-physical domain in men who sustained main fractures at the hip. Subclinical vertebral fractures exerted a moderate effect on HRQL... - Efficacy of lumiracoxib in osteoarthritis: a review of nine studiesF Berenbaum
Department of Rheumatology, Pierre and Marie Curie University Saint Antoine Hospital, Paris, France
J Int Med Res 33:21-41. 2005..These were used to provide a single measure of response to treatment, taking into account pain, the patient's global assessment of disease activity and functional status... - Efficacy and tolerability of lumiracoxib versus placebo in patients with osteoarthritis of the handJ K Grifka
Orthopaedische Klinik, , Bad Abbach, Germany
Clin Exp Rheumatol 22:589-96. 2004..Lumiracoxib significantly improved overall OA pain intensity in the target hand versus placebo, with a tolerability profile similar to placebo... - The association between osteoporotic fractures and health-related quality of life as measured by the Health Utilities Index in the Canadian Multicentre Osteoporosis Study (CaMos)J D Adachi
Department of Medicine, St Joseph s Hospital, McMaster University, Charlton Avenue East, Suite 501, L8 N 1Y2 Hamilton, Ontario, Canada
Osteoporos Int 14:895-904. 2003..06; 95% CI: -0.11, -0.00) for women, and rib fractures (-0.06; 95% CI: -0.12, -0.00) for men. In conclusion, this study demonstrates a negative association between osteoporotic fractures and quality of life in both women and men...